USA AFTER FRANCE ADVOCATING FOR GENERIC MEDICINES FOR POOR HIV CANCER PATIENT BUT OUR GOVT PLANNING TO CLOSE
- Get link
- Other Apps
USA AFTER FRANCE ADVOCATING FOR GENERIC MEDICINES FOR POOR HIV CANCER PATIENT BUT OUR GOVT PLANNING TO CLOSE
PROF.DRRAM ,HIV/AIDS,SEX Diseases, Weakness & Hepatitis Expert
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
The ever-increasing costs of drugs may be brought under more control with the delivery of reliable, effective, and cheaper generics. Why do we continue to spend billions of dollars for brand-name drugs that are available in cheaper generic forms in the developing world -- billions that end up as profits for pharmaceutical industry? A generic drug has the same active ingredients as the original, brand-name drug and is comparable to the branded drug in dosage, form, strength, and quality. The FDA requires that generic drugs be identical or fall within an acceptable range of their brand-name counterparts.
In a 2013 article in the Annals of Internal Medicine, Rochelle Walensky estimated that savings of close to one billion dollars a year could be achieved if all people with HIV in the U.S. took generic antiretrovirals (ARVs). Replacing Atripla with a generic three-pill alternative was projected to lead to an average lifetime savings of $42,500 for each patient.
To discuss the issue of generic ARVs and their place in HIV care, the Forum for HIV Collaborative Research and its partners, HIVMA and ACRIA, recently held a one-day conference in Washington D.C., "Use of Generic Antiretrovirals for Treatment of HIV in the United States." In attendance were policy makers, government regulators, physicians, and scientists.France is an example of a country that does consider cost in its HIV treatment guidelines. The generic raltegravir is listed as an alternative for Isentress in the French guidelines. These guidelines recommend that Atripla be replaced by generic efavirenz and lamivudine, along with brand-name Viread.
In the developing world the use of generic ARVs is key to reaching the goal of an AIDS-free generation. PEPFAR, the President's Emergency Plan For AIDS Relief, has helped save the lives of millions of people with HIV the world over. Under this program, the FDA approves generic ARVs for distribution in other countries, even if they are still under patent in the U.S. These drugs cannot, however, be re-imported or marketed in the U.S. The FDA's Office of Generic Drugs maintains the same standards for generic ARVs as it does for branded drugs in the U.S. PEPFAR generic drugs meet all of the FDA's manufacturing, quality, safety, and efficacy requirements.BUT IN OUR COUNTRY WHICH MANUFACTURE SO MANY CANCER AND HIV GENERIC MEDICINES UNDER PRESSURE FROM USA UNDER PATENT RIGHT WANT TO CLOSE SUCH PRODUCTION AND SENDING IT TO POOR DEVELOPING COUNTRIES TO BENEFIT USA COMAPNIES UNDER MODI OBAMA FRIENDSHIP.
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
The ever-increasing costs of drugs may be brought under more control with the delivery of reliable, effective, and cheaper generics. Why do we continue to spend billions of dollars for brand-name drugs that are available in cheaper generic forms in the developing world -- billions that end up as profits for pharmaceutical industry? A generic drug has the same active ingredients as the original, brand-name drug and is comparable to the branded drug in dosage, form, strength, and quality. The FDA requires that generic drugs be identical or fall within an acceptable range of their brand-name counterparts.
In a 2013 article in the Annals of Internal Medicine, Rochelle Walensky estimated that savings of close to one billion dollars a year could be achieved if all people with HIV in the U.S. took generic antiretrovirals (ARVs). Replacing Atripla with a generic three-pill alternative was projected to lead to an average lifetime savings of $42,500 for each patient.
To discuss the issue of generic ARVs and their place in HIV care, the Forum for HIV Collaborative Research and its partners, HIVMA and ACRIA, recently held a one-day conference in Washington D.C., "Use of Generic Antiretrovirals for Treatment of HIV in the United States." In attendance were policy makers, government regulators, physicians, and scientists.France is an example of a country that does consider cost in its HIV treatment guidelines. The generic raltegravir is listed as an alternative for Isentress in the French guidelines. These guidelines recommend that Atripla be replaced by generic efavirenz and lamivudine, along with brand-name Viread.
In the developing world the use of generic ARVs is key to reaching the goal of an AIDS-free generation. PEPFAR, the President's Emergency Plan For AIDS Relief, has helped save the lives of millions of people with HIV the world over. Under this program, the FDA approves generic ARVs for distribution in other countries, even if they are still under patent in the U.S. These drugs cannot, however, be re-imported or marketed in the U.S. The FDA's Office of Generic Drugs maintains the same standards for generic ARVs as it does for branded drugs in the U.S. PEPFAR generic drugs meet all of the FDA's manufacturing, quality, safety, and efficacy requirements.BUT IN OUR COUNTRY WHICH MANUFACTURE SO MANY CANCER AND HIV GENERIC MEDICINES UNDER PRESSURE FROM USA UNDER PATENT RIGHT WANT TO CLOSE SUCH PRODUCTION AND SENDING IT TO POOR DEVELOPING COUNTRIES TO BENEFIT USA COMAPNIES UNDER MODI OBAMA FRIENDSHIP.
Comments
Post a Comment